Blood marker may help doctors spot and treat respiratory failure before it worsens
NCT ID NCT07334379
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether measuring a blood marker called interleukin-6 (IL-6) can help doctors decide when to give anti-inflammatory drugs to patients hospitalized with acute respiratory failure. Patients with high IL-6 levels will receive either standard care, a single dose of tocilizumab, or a 10-day course of dexamethasone. The goal is to see if this approach is practical and can prevent the need for intensive care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tocilizumab (Actemra) and dexamethasone
What this could lead to
If successful, this approach could help doctors identify high-risk patients earlier and start targeted anti-inflammatory treatment to prevent severe complications like organ failure.
What could go wrong
This is a small, early feasibility study with only 60 participants, so results may not apply broadly. The treatments also carry risks like infection or side effects from steroids.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE HYPOXEMIC RESPIRATORY FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Toronto General Hospital
RECRUITINGToronto, Ontario, M5G 2N2, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact